REGULATORYSTORY 632· AUGUST 4, 2026

Palvella Therapeutics files first NDA module for rare lymphatic disease drug, holds $250.6 million in cash

A drug application that lets the FDA begin reviewing completed portions before the full package arrives has reached federal regulators for a treatment targeting a serious, rare condition with no approved therapies in the United States…

NDNewsDialy Desk3 MIN READPVLA

SOURCE

sec.gov

← PREVIOUS STORY 631Trump warns Iran talks are a 'last chance' as Bessent says Hormuz deal is in sight NEXT STORY 633 →BP to sell $4 billion US biogas business as profits more than double

Keep reading

More from the desk.

11REGULATORY

Judge rejects hindsight defense in Silicon Valley Bank collapse case

Hindsight, in a legal proceeding, means assigning blame using knowledge that emerged only after events unfolded, rather than by what a person could reasonably have known at the time. A federal judge has rejected that defense in the case…

regulatory1 MIN

12REGULATORY

GOP splits over cash for new mothers as guaranteed income debate moves past party lines

A growing number of Republican lawmakers are backing guaranteed income programs for pregnant women and new mothers, even as their own party moves to ban them in at least five states. Guaranteed income means giving families money with few…

regulatory2 MIN

14REGULATORY

Paramount in talks to settle antitrust suit blocking Warner Bros. Discovery deal

State legal action has been the obstacle keeping Paramount and Warner Bros. Discovery from completing their proposed merger. Paramount is in talks to resolve an antitrust lawsuit, a legal challenge asserting the deal would harm…

regulatory1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk